Evidence map›Paper›PMID 42298224›Full record

ArticleMolecular imaging and biology2026

Preclinical Evaluation of [

Chunfang A Xia, Wei Zhang, Tamara Berdyyeva, Chaofeng Huang, Michael K Ameriks, Terry P Lebold, Michael P Maher, Cristian C Constantinescu, Leslie Nguyen, Nyantsz Wu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chunfang A XiaDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Wei ZhangDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Tamara BerdyyevaNeuroscience Discovery, Johnson & Johnson, San Diego, CA, USA.
Chaofeng HuangDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Michael K AmeriksGlobal Discovery Chemistry, Johnson & Johnson, San Diego, CA, USA.
Terry P LeboldGlobal Discovery Chemistry, Johnson & Johnson, San Diego, CA, USA.
Michael P MaherNeuroscience Discovery, Johnson & Johnson, San Diego, CA, USA.
Cristian C Constantinescu, Perceptive, New Haven, CT, USA.
Leslie NguyenPreclinical Sciences and Translational Safety, Johnson & Johnson, San Diego, CA, USA.
Nyantsz WuNeuroscience Discovery, Johnson & Johnson, San Diego, CA, USA.
Gang ChenDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Hartmuth C KolbNeuroscience Discovery, Johnson & Johnson, San Diego, CA, USA.
Anna Katrin SzardeningsDiscovery Technologies and Molecular Pharmacology, Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA. aszarden@its.jnj.com.ORCID http://orcid.org/0000-0002-9887-7868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe AMPA receptor (AMPARs) mediates fast excitatory neurotransmission and is the central to synaptic plasticity, learning and memory dysregulation of this system has been implicated in epilepsy, neurodegeneration, and neuropsychiatric disorders. The transmembrane AMPA receptor regulatory protein γ8 (TARP γ8) plays a crucial role in the expression and localization of AMPARs within the brain, particularly in the hippocampus and cortex. A selective positron emission tomography (PET) ligand to image this target is of significant interest for investigating potential clinical AMPAR/TARP γ8 antagonists. This study describes the development and preclinical evaluation of a potent and selective tracer targeting TARP γ8, [ PROCEDURES: The binding potency of JNJ-1 was evaluated using a calcium flux assay in HEK-293 cells. The radiotracer was synthesized on an automated synthesizer via a one-step substitution. TARP γ8 target expression in brains was confirmed through immunohistochemistry (IHC), and adjacent brain sections were used for autoradiography (ARG). In vivo assays were conducted in rats, knockout mice, and non-human primates by [

resultsJNJ-1 exhibited very high binding potency to TARP γ8, IC

conclusion[

Indexed as

[18F]JNJ-1AMPAR/TARP γ8Non-human primate imagingPositron emission tomographyReceptor occupancy

Identifiers

PMID42298224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.